{'fraction_non_alphanumeric': 0.02608695652173913, 'fraction_numerical': 0.009937888198757764, 'mean_word_length': 5.5, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Regression of nephrotic syndrome with colchicine therapy secondary to amyloidosis with associated Castleman's disease.

This report describes a patient with Castleman’s disease (CD) of mixed hyaline vascular type at the mesentery of the jejunum associated with systemic amyloidosis. Potassium permanganate-sensitive amyloid deposition was found on the vascular walls of the rectal mucosa and mesenteric lymphoid mass. After surgical resection of the mesenteric mass, nephrotic syndrome (NS) continued. With colchicine therapy, clinical and laboratory manifestations improved. She is asymptomatic and disease free for 23 months. CD was first described in detail by Cas-tleman al. 1956 and is also known as lymph node hamartoma, angiofollicular lymph node hyperplasia and giant lymph node hyperplasia [2]. 5